Ticagrelor Tablet, Film Coated
Product Images NDC 69097-991

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 69097-991). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

60mg 100 Count. (60mg 100 Count)

Ticagrelor 60 mg film-coated tablets label showing a package of 100 tablets. The label includes storage instructions, warnings, and manufacturer information, with Cipla USA Inc. as the labeler. It features a barcode and emphasizes the prescription nature of the product.*

FDA Label Image

60mg 500 Count. (60mg 500 Count)

Label for Ticagrelor Tablets 60 mg oral film-coated tablets, containing 500 tablets per package. The label includes storage instructions, dispensing information, warnings to keep out of reach of children, and manufacturing details by Cipla USA Inc. and InvaGen Pharmaceuticals, Inc. A barcode and lot/expiration date fields are visible.*

FDA Label Image

60mg 60 Count. (60mg 60 Count)

Label for Ticagrelor Tablets 60 mg film-coated oral tablets, containing 60 tablets per bottle. The label includes storage instructions, a warning to keep out of reach of children, and manufacturer information: InvaGen Pharmaceuticals, Inc. and Cipla USA Inc. A barcode and the statement 'No Varnish' are also visible.*

FDA Label Image

90mg 100 Count. (90mg 100 Count)

Ticagrelor Tablets 90 mg film-coated tablets packaging label. The label indicates 100 tablets per container and includes storage instructions, warnings, and dispensing information. Manufactured by InvaGen Pharmaceuticals and labeled for Cipla USA Inc. The label displays an NDC code, barcode, and a notice that no varnish is applied to the package.*

FDA Label Image

90mg 500 Count. (90mg 500 Count)

Label for Ticagrelor Tablets 90 mg, film-coated oral tablets by Cipla USA Inc. The label includes directions for pharmacists, tablet quantity of 500, storage instructions, warnings, and manufacturer information for InvaGen Pharmaceuticals, Inc. A barcode and NDC 69097-991-12 are shown.*

FDA Label Image

90mg 60 Tablets. (90mg 60 Tablets)

Label for Ticagrelor 90 mg film-coated tablets by Cipla USA Inc. The label indicates a package of 60 tablets, with storage instructions, warning to keep tightly closed and out of reach of children, and directs pharmacists to dispense the Medication Guide separately. It includes manufacturer details and a barcode.*

FDA Label Image

Fig 10. (Fig 10)

A Kaplan-Meier survival curve chart comparing cumulative event percentages over 360 days from randomization between Ticagrelor 90 mg and Clopidogrel 75 mg. The x-axis represents days from randomization, and the y-axis shows cumulative percentage events. Ticagrelor shows a lower cumulative event rate than Clopidogrel throughout the period.*

FDA Label Image

Fig_1 (Fig 1)

A cumulative percentage line graph comparing two treatments, labeled Ti 90 mg and Clopidogrel, over 360 days from the first study drug dose. The graph includes patient numbers at risk over time and a data table summarizing the number of patients with events and Kaplan-Meier estimates at 12 months for each treatment group.*

FDA Label Image

Fig_11. (Fig 11)

A forest plot illustrating the hazard ratios (HR) with 95% confidence intervals for various patient characteristics comparing Ticagrelor and Clopidogrel treatment effects. Categories include geographic region, ASA dose, treatment approach, diabetes history, age group, sex, and race, showing the relative effectiveness of Ticagrelor versus Clopidogrel.*

FDA Label Image

Fig_12. (Fig 12)

A forest plot comparing the hazard ratios (HR) with 95% confidence intervals (CI) for Ticagrelor versus Clopidogrel across different ASA dose categories (>=300 mg, >100 to <300 mg, <=100 mg) in US and Non-US regions. The plot visualizes the relative effectiveness of Ticagrelor compared to Clopidogrel, with sample sizes and event counts listed.*

FDA Label Image

Fig_13. (Fig 13)

A cumulative percentage line graph showing events over days from randomization for Ticagrelor 60 mg, Ticagrelor 90 mg, and Placebo groups. The X-axis represents days (up to about 1320), and the Y-axis shows cumulative percentage of patients with events. A table below lists the number of patients at risk over time for each group. An inset box provides patient counts, event percentages, hazard ratios with confidence intervals, and p-values for each group.*

FDA Label Image

Fig_14. (Fig 14)

A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus placebo across multiple patient subgroups. The variables include overall treatment effect, age groups, sex, race, weight, BMI, region, history of myocardial infarction, type of qualifying MI, diabetes, renal function, history of PCI, stent types, and ADP receptor blocker treatment duration. The chart shows the relative effect of Ticagrelor compared to placebo, with data points mostly favoring Ticagrelor.*

FDA Label Image

Fig_15. (Fig 15)

A cumulative percentage line graph comparing the outcomes of Ticagrelor versus placebo over a period of 54 months from randomization. The x-axis represents months, and the y-axis shows cumulative percentage. The graph includes a legend indicating Ticagrelor and placebo groups with respective event counts and total participants. Risk numbers at different time points are displayed below the x-axis.*

FDA Label Image

Fig_16. (Fig 16)

A forest plot chart comparing the effect of Ticagrelor versus placebo across various patient subgroups, including age, sex, race, body mass index, geographic region, aspirin dose, HbA1c level, kidney function, insulin use, cardiovascular history, stent type, smoking status, and diabetes duration. The plot displays hazard ratios with confidence intervals on a logarithmic scale.*

FDA Label Image

Fig_17. (Fig 17)

A cumulative percentage line graph comparing Ticagrelor 90 mg twice daily (solid line) to placebo (dashed line) over approximately 33 days. The x-axis represents days from randomization, and the y-axis shows cumulative percentage. The graph includes event counts and hazard ratios (KM %) for both groups, as well as numbers at risk over time.*

FDA Label Image

Fig_18. (Fig 18)

A forest plot chart comparing hazard ratios (HR) with 95% confidence intervals (CI) of Ticagrelor versus placebo across multiple patient subgroups and characteristics including age, sex, race, BMI, geographic region, diagnosis, NIHSS stroke scores, time intervals related to treatment, risk factors, and prior treatments. The plot visually indicates subgroup comparisons of Ticagrelor efficacy and safety outcomes relative to placebo.*

FDA Label Image

Fig_2. (Fig 2)

A bar chart illustrating the percentage of patients who experienced an event following CABG over several days. The x-axis represents days (1 to 7 and >=8), and the y-axis represents the percentage of patients. Two groups, labeled T and C, are compared across the days, with numerical data provided below the chart.*

FDA Label Image

Fig_3. (Fig 3)

A line chart comparing cumulative percentage events over months from randomization between Ticagrelor and placebo groups. The x-axis shows months from 0 to 54, and the y-axis represents cumulative percentage (0% to 7%). Two lines represent Ticagrelor (solid) and placebo (dashed), with Ticagrelor generally showing higher event percentages. Patient risk numbers are displayed below the x-axis for each group over time.*

FDA Label Image

Fig_4. (Fig 4)

A cumulative percent graph comparing Ticagrelor 90 mg twice daily vs placebo over days from randomization, showing the number of events and Kaplan-Meier percentages. The x-axis is labeled 'Days from randomization' and the y-axis is labeled 'Cumulative %'. Risk data numbers are shown below the x-axis.*

FDA Label Image

Fig_5. (Fig 5)

A line graph comparing IPA (%) induced by 20 µM ADP over time (hours) for Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. Ticagrelor shows a rapid and high increase in IPA reaching around 90%, Clopidogrel shows a moderate increase, and Placebo shows minimal change over 8 hours.*

FDA Label Image

Fig_6. (Fig 6)

A line graph comparing platelet inhibition activity (IPA %) induced by 20uM ADP over time between Ticagrelor, Clopidogrel, and Placebo groups. The main graph shows IPA over days up to 10, with Ticagrelor and Clopidogrel showing higher percentages than Placebo. An inset graph shows IPA over hours up to 48, highlighting initial differences in inhibition among the three groups.*

FDA Label Image

Fig_7. (Fig 7)

A forest plot chart titled 'Mean effect and 90% CI' showing the impact of intrinsic factors like age, gender, ethnicity, renal impairment, end-stage renal disease, and hepatic impairment on the pharmacokinetics of Ticagrelor. The chart compares changes in Cmax, AUC, and clearance, with recommendations indicating no dose adjustments are needed for any factors.*

FDA Label Image

Fig_8. (Fig 8)

A chart titled 'Mean effect and 90% CI' comparing the interaction effects of various drugs on Ticagrelor and AR-C124910XX. The chart plots changes relative to reference using pharmacokinetic parameters Cmax and AUC, with drug interactions listed on the left and corresponding recommendations on the right, including dose adjustments and concomitant use advisories.*

FDA Label Image

Fig_9. (Fig 9)

A chart showing the mean effect and 90% confidence interval of various interacting drugs on Ticagrelor dose. The x-axis represents change relative to interacting drug alone, with markers for Cmax and AUC. Recommendations for dose adjustments are listed for drugs such as Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine.*

FDA Label Image

Structure. (Structure)

Chemical structure of Ticagrelor, showing its characteristic rings, functional groups, and fluorine atoms as part of its molecular formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.